Overview of quadrivalent immunization in female adolescents against Human Papillomavirus over four years: a cross-region analysis in Brazil
DOI:
https://doi.org/10.33448/rsd-v11i8.30442Keywords:
HPV; Quadrivalent Vaccine; Girls; Epidemiological Surveillance; Brazil.Abstract
Introduction: Human Papillomavirus is one of the major etiologies of sexually transmitted infections and oncogenic diseases in the world, in which it has low and high oncogenic risk viral serotypes (HPV-6, -11, -16 and -18). Many vaccines were developed to contain the spread of infection, among them, the quadrivalent, which provides protection to these viral serotypes. However, vaccination coverage of the immunizer in Brazil is unsatisfactory in different regions of the country, especially in the female adolescent group. Objective: To describe the panorama of female quadrivalent vaccination among Brazilian regions over four years. Methodology: Data were obtained from the public database TABNET - Immunizations, considering: all regions, period from 2016 to 2019, quadrivalent immunizer HPV-female-1st/2nd-doses and age from 10 to 15 years. Data were organized in an Excel spreadsheet and analyzed in RStudio software, in which all the graphic language was produced. Results: It was observed that the number of applications increased in the first biennium of the analysis, but significantly reduced in the second, in addition to the fact that the vaccine scenario of the first dose does not follow the second, directly reflecting the vaccine coverage of the immunizer in the country. Conclusion: the research graphically demonstrated the female quadrivalent vaccine scenario, showing that it is unsatisfactory, since recent studies also highlight the existing gaps in vaccine coverage, in addition to citing the regional heterogeneity regarding the vaccination reality of each location in the Brazil.
References
BRASIL. Ministério da saúde. Secretaria de Vigilância em Saúde. Departamento de Vigilância das Doenças Transmissíveis (2014). Manual de normas e procedimentos para a vacinação. https://bvsms.saude.gov.br/bvs/publicacoes/manual_procedimentos_vacinacao.pdf.
Controle e Prevenção de Doenças [CDC]. (2021). Human Papillomavirus. https://www.cdc.gov/vaccines/pubs/pinkbook/hpv.html#:~:text=On%20average%2C%2043%2C999%20HPV%2Dassociated,11%2C300%20oropharyngeal%20cancers%20in%20men.
Fedrizzi, E. N. (2017). Desinformação sobre a vacina contra o HPV. http://www.hu.ufsc.br/setores/projetohpv/2017/12/28/desinformacao-sobre-a-vacina-contra-o-hpv/.
Herfs, M., Soong, T. R., Delvenne, P., & Crum, C. P. (2017). Deciphering the Multifactorial Susceptibility of Mucosal Junction Cells to HPV Infection and Related Carcinogenesis. Viruses, 9(4), 85. https://doi.org/10.3390/v9040085.
Instituto Brasileiro de Geografia e Estatística [IBGE]. (2019). Ministério do Planejamento, Orçamento e Gestão. Pesquisa Nacional de Saúde do Escolar 2019 - Tema 8 - Saúde Sexual e Reprodutiva. https://ftp.ibge.gov.br/pense/2019/xls/Tema_08_Saude_Sexual_e_Reprodutiva.xls.
Instituto Nacional do Câncer [INCA]. (2022). Existe vacina contra o HPV?. https://www.inca.gov.br/perguntas-frequentes/existe-vacina-contra-o-hpv#:~:text=O%20Minist%C3%A9rio%20da%20Sa%C3%BAde%2C%20em,idade%2C%20com%20a%20vacina%20quadrivalente.
International Committee on Taxonomy of Viruses (ICTV). (2021). Virus Taxonomy: 2021 Release. https://talk.ictvonline.org/taxonomy/.
Lipold, L., Sikon, A. & Rome, E. (2013). Human papillomavirus vaccine: safe, effective, underused. Cleveland Clinic journal of medicine, 80(1), 49.
Lopalco, P. L. (2017). Spotlight on the 9-valent HPV vaccine. Drug design, development and therapy, 11, 35.
Ministério da Saúde. Secretaria de Vigilância em Saúde. Departamento de Vigilância de Doenças Transmissíveis. Coordenação Geral do Programa Nacional de Imunizações. (2019). Guia Prático sobre o HPV: Guia de Perguntas e Respostas para Profissional de Saúde. Brasília: DF. https://www.inca.gov.br/sites/ufu.sti.inca.local/files//media/document//guia-pratico-hpv-2013.pdf.
Mizuta, A. H., Succi, G. D. M., Montalli, V. A. M., & Succi, R. C. D.M. (2018). Percepções acerca da importância das vacinas e da recusa vacinal numa escola de medicina. Revista Paulista de Pediatria, 37, 34-40.
Moura, L. D. L. (2019). Cobertura vacinal contra o Papilomavírus Humano (HPV) em meninas e adolescentes no Brasil: análise por coortes de nascimentos. Tese (Doutorado).
Moura, L. de L., Codeço, C. T., & Luz, P. M. (2021). Cobertura da vacina papilomavírus humano (HPV) no Brasil: heterogeneidade espacial e entre coortes etárias. https://doi.org/10.1590/1980-549720210001.
Neto, L. A. A. (2021). Vacina, antivacinismo e biopoder: a história e os estratos do tempo. Physis: Revista de Saúde Coletiva, Rio de Janeiro, v. 31(4), e310425.
Oliveira, G. S., Bitencourt, E. L., Amaral, P. F. F., Vaz, G. P., & Reis, J. P. M. (2020). Cobertura vacinal: uma análise comparativa entre os estados da Região Norte do Brasil. Revista de Patologia do Tocantins, 7(1) p. 14-17.
R Core Team. (2018). R: A language and environment for statistical computing. R Foundation for Statistical Computing. Vienna, Austria. https://www.R-project.org/.
Santos, J. G. S. & Dias, J. M. G. (2018). Vacinação pública contra o papilomavirus humano no Brasil. Rev Med Minas Gerais, 28(1), 1-7.
Santos, M. de O. (2018). Estimativa 2018: Incidência de Câncer no Brasil. Rev. Bras. Cancerol., 64(1):119-20. https://rbc.inca.gov.br/index.php/revista/article/view/115.
Secretaria de Estado de Saúde. Governo do Estado de Goiás. (2016). Ministério da Saúde começa a vacinar meninos contra HPV em 2017. https://www.saude.go.gov.br/noticias/3705-ministerio-da-saude-comeca-a-vacinar-meninos-contra-hpv-em-2017.
Silva, M. R. B., Conceição, A. S. F., Silva, D. M., Araujo R., A. D., Andrade, J. G., Reis, T. L., &Souza, R. S. (2020). Eventos adversos pós-vacinais papilomavírus humano em adolescentes. Saúde Coletiva, 10(53), p. 2470-2489.
Sociedade Brasileira de Imunizações [SBIM]. (2020). Coberturas vacinais no Brasil são baixas e heterogêneas, mostram informações do PNI. https://sbim.org.br/noticias/1359-coberturas-vacinais-no-brasil-sao-baixas-e-heterogeneas-mostram-informacoes-do-pni#:~:text=Em%202020%2C%20a%20primeira%20dose,aproximadamente%2040%25%20e%2030%25.
Sousa, A. R. de A., Alves, A. A. C., Mamede A. L., Maciel, C. N. A. T., Marques, D. M. S., Talassi G. G., Pinheiro L. S., Rios M. S., Melo P. P. M. de, & Moura, A. de A. (2021). Estudo Epidemiológico sobre Hepatite na Região Nordeste entre 2010 a 2018 através de dados do DATASUS. Revista Eletrônica Acervo Médico, 1(2), e9391. https://doi.org/10.25248/reamed.e9391.2021.
World Health Organization [WHO]. (2017). Global Health Sector Strategy on Sexually Transmitted Infections 2016-2021: Implementation Framework for the African Region - Secretariat Report (No. AFR/RC67/7). Regional Office for Africa.
Yim, E.-K. & Park, J.-S. (2005). The role of HPV E6 and E7 oncoproteins in HPV- associated cervical carcinogenesis. Cancer research and treatment: official journal of Korean Cancer Association, v. 37, n. 6, p. 319.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Renata Suellen Souza Cauper Viana; Sergio Augusto Antunes Ramos; Patrícia Michelly Mendonça Viana; André Luiz Bittencourt de Amorim Farias; Natasha Ponte Tabosa; Maria Luana Alcantara Benevides; Waldilene Valente Silva; Waldirene Ferreira Monteiro; Julyana Lago Pinto da Silva; Wallex da Silva Guimarães; Beatriz Oliveira Amaro
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
